Business
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunotherapy – – All PD-(L)1 re
About this update from Sensei Biotherapeutics, Inc.
[{"type":"image","alt":"Sensei Biotherapeutics","displaySize":"","headline":null,"caption":"Sensei Biotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":111,"url":"https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tSVB9mWPe6cbY7LRif6RFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405","width":300,"height":111}},"lazy":false},{"type":"text","content":"– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing –","length":179,"tagName":"p"},{"type":"text","content":"– One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunotherapy –","length":303,"tagName":"p"},{"type":"text","content":"– All PD-(L)1 resistant “hot” tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time –","length":139,"tagName":"p"},{"type":"text","content":"– Sensei to host investor webcast today at 5:30 p.m. ET –","length":57,"tagName":"p"},{"type":"text","content":"BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug (formerly SNS-101), a conditionally active monoclonal antibody targeting VISTA (V-domain Ig suppressor of T cell activation).","length":472,"tagName":"p"},{"type":"text","content":"“Checkpoint inhibitor resistance remains a significant challenge for patients with advanced cancer, with limited treatment options beyond chemotherapy or clinical trials,” said Ron Weitzman, M.D., Chief Medical Officer of Sensei Biotherapeutics. “Historically, patients who progress on PD-(L)1 therapy are estimated to have a ≤5% likelihood of response to PD-(L)1 rechallenge, making this an ext...